After rising to greatness following the launch of multiple hepatitis C drugs, sales have slipped, and Gilead Sciences (NASDAQ: GILD) shares have been knocked down to levels not seen since 2014. Here are three …
Gilead’s stock now trades at a high-single digit price-to-earnings multiple which typically has many bargain hunters salivating, especially in a market where many quality blue-chip stocks and dividend aristocrats trade …
Dividend
Gilead Sciences, Inc. (NASDAQ:GILD) CEO John F. Milligan sold 112,000 shares of the company’s stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $94.59, for a total transaction …
Gilead Sciences Inc. (GILD) down -12.99 per cent in the past week, is under coverage of 25 analysts who collectively recommend a hold rating on stock. 17 of the analysts have a buy or better rating; the 8 sells …
as it continues to snap up customers and pressure its competitors. Shares gained 0.8% to $61.38 in premarket trading. Gilead Sciences’ stock rose 1.6% to $68.70
Gilead Sciences
Shelley Shapiro, MD, has speaker and consulting agreements with …
Cialis
Gilead Sciences Inc. (NASDAQ:GILD) is scheduled to report third-quarter 2016 results on Nov 1, after the market closes. Last quarter, the company had surpassed expectations with a positive earnings surprise of 0.33%. …
Gilead Sciences stock tells a cautionary tale about putting all your eggs in one basket. The drugmaker is among the most prolific and successful in the world... but it makes nearly all of its revenue from HIV and hepatitis C …
Stock
Simon provides outperforming buy and sell opinions on stocks, currencies, bonds, commodities, and real estate. His in-depth research covers most of the major financial markets in America. His research is based on the …
[Reuters] – Massachusetts’ attorney general is studying whether the prices of Gilead Sciences Inc’s …